| 1 |
Mitsuma SF, Mansour MK, Dekker JP, et al. Promising new assays and technologies for the diagnosis and management of infectious diseases[J]. Clin Infect Dis, 2013, 56(7): 996-1002.
|
| 2 |
Wirz Y, Meier MA, Bouadma L, et al. Effect of procalcitonin-guided antibiotic treatment on clinical outcomes in intensive care unit patients with infection and sepsis patients: a patient-level meta-analysis of randomized trials[J]. Crit Care, 2018, 22(1): 191.
|
| 3 |
阿地兰·艾尔肯，王毅，于湘友. 血清降钙素原及其清除率对自体肝移植受者术后早期感染的诊断价值[J/CD]. 中华移植杂志：电子版，2018，12(1)：9-13.
|
| 4 |
Sandkovsky U, Kalil AC, Florescu DF. The use and value of procalcitonin in solid organ transplantation[J]. Clin Transplant, 2015, 29(8): 689-696.
|
| 5 |
郁玲玲，王婷，方浩，等. 肝移植术后降钙素原水平的变化特点及其对术后感染的诊断价值[J]. 中国临床医学，2016，23(2)：157-160.
|
| 6 |
Eyraud D, Ben Ayed S, Tanguy ML, et al. Procalcitonin in liver transplantation: are high levels due to donors or recipients？[J]. 2008, 12(4): R85.
|
| 7 |
马琛，曹彬，栗方，等. 降钙素原动态监测对肝移植术后感染并发症的诊断价值[J]. 中华内科杂志，2009，48(5)：406-407.
|
| 8 |
Kaido T, Ogawa K, Fujimoto Y, et al. Perioperative changes of procalcitonin levels in patients undergoing liver transplantation[J]. Transpl Infect Dis, 2014, 16(5): 790-796.
|
| 9 |
Pereira MR, Scully BF, Pouch SM, et al. Risk factors and outcomes of carbapenem-resistant Klebsiella pneumoniae infections in liver transplant recipients[J]. Liver Transpl, 2015, 21(12): 1511-1519.
|
| 10 |
Geng TT, Xu X, Huang M. High-dose tigecycline for the treatment of nosocomial carbapenem-resistant Klebsiella pneumoniae bloodstream infections: A retrospective cohort study[J]. Medicine (Baltimore), 2018, 97(8): e9961.
|
| 11 |
Castanheira M, Mendes RE, Sader HS. Low frequency of ceftazidime-avibactam resistance among Enterobacteriaceae isolates carrying blaKPC collected in U. S. hospitals from 2012 to 2015[J]. Antimicrob Agents Chemother, 2017, 61(3): e02369-16.
|
| 12 |
Van Duin D, Lok JJ, Earley M, et al. Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae[J]. Clin Infect Dis, 2018, 66(2): 163-171.
|
| 13 |
Haidar G, Clancy CJ, Shields RK, et al. Mutations in blaKPC-3 that confer ceftazidime-avibactam resistance encode novel KPC-3 variants that function as extended-spectrum β-lactamases[J]. Antimicrob Agents Chemother, 2017, 61(5): e02534-16.
|